Vanderbilt
Welcome,         Profile    Billing    Logout  
 108 Trials 
179 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stein, Charles
NCT03649178: Dietary Salt in Rheumatoid Arthritis

Completed
N/A
18
US
salt
Vanderbilt University Medical Center, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
09/24
12/24
Lee, Stephanie J
NCT04572815: Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Recruiting
2
116
US
Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Ustekinumab, CNTO 1275, CNTO1275, Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer, Stelara
Fred Hutchinson Cancer Center
Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
03/26
09/27
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
12/25
01/27
NCT05996627: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Recruiting
2
82
US
Belumosudil, KD 025, KD-025, KD025, Rho-associated Coiled-coil Kinase 2 Inhibitor KD025, ROCK-II Inhibitor KD025, ROCK2 Inhibitor KD025, SLx 2119, SLx-2119, SLx2119, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Placebo Administration
Fred Hutchinson Cancer Center, Sanofi
Chronic Graft Versus Host Disease
05/27
12/27
NCT04111497: Glasdegib for Chronic Graft-Versus-Host Disease

Terminated
1/2
15
US
Glasdegib, 1095173-27-5, PF 04449913, PF-04449913, PF04449913
Fred Hutchinson Cancer Center, Pfizer
Chronic Graft Versus Host Disease, Fasciitis
08/23
08/23
NCT00637689: Improving Outcomes Assessment in Chronic GVHD

Active, not recruiting
N/A
601
US
Fred Hutchinson Cancer Center, University of Minnesota, Stanford University, Dana-Farber Cancer Institute, Vanderbilt University, Medical College of Wisconsin, Washington University School of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
05/17
02/27
NCT01902576: Chronic GVHD Response Measures Validation

Active, not recruiting
N/A
383
US
Fred Hutchinson Cancer Center
Graft vs Host Disease
09/19
02/27
PROHIBIT-ICH, NCT03863665: Prevention of Hypertensive Injury to the Brain by Intensive Treatment of Blood Pressure After Intracerebral Haemorrhage

Terminated
N/A
86
Europe
A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci
University College, London, University of Oxford, The Stroke Association, United Kingdom
Intracerebral Hemorrhage
05/22
04/23
NCT06202677: Effectiveness of a Self-guided Mobile Application in Improving Obsessive Compulsive Disorder Symptoms

Active, not recruiting
N/A
225
RoW
Self-guided program on obsessive compulsive disorder, Self-guided program on cooperation
National University of Singapore, Intellect Pte. Ltd.
Obsessive-Compulsive Disorder
03/24
07/24
BMT CTN 1702, NCT03904134: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

Active, not recruiting
N/A
1753
US
Donor Search Prognosis Score
Center for International Blood and Marrow Transplant Research, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program, Medical College of Wisconsin
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease
06/24
03/25
CATCH, NCT04188912: Close Assessment and Testing for Chronic Graft Versus Host Disease, Study

Active, not recruiting
N/A
267
US
Biospecimen Collection, Optical Coherence Tomography, OCT, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Quality of Life Assessment, Medical Chart Review, Chart Review
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm
10/25
10/25
NCT04431479: Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Recruiting
N/A
200
Canada, US
Biospecimen Collection, Medical Chart Review, Chart Review, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
08/26
08/26
Berlin, Jordan
NCT03641313: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Active, not recruiting
2
14
US
Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970, Computed Tomography Assisted Biopsy, Computed Tomography Biopsy, Computed Tomography-Guided Needle Biopsy, CT Assisted Biopsy, CT Guided Biopsy, Endoscopic Biopsy, Endoscopy and Biopsy, Irinotecan, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
07/24
12/25
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT03263429: Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Completed
1/2
29
US
Glutaminase Inhibitor CB-839, Panitumumab, Irinotecan Hydrochloride (phase I only), Laboratory Biomarker Analysis, Pharmacological Study, Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Calithera Biosciences, Inc
Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer, Refractory Colorectal Cancer
08/23
12/23
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Eli Lilly and Company, Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
NCT05121948: A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Terminated
1
35
US
HC-7366
HiberCell, Inc., Covance
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
02/24
03/24
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
Barker, Colin
CAMEO, NCT04076813: Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Active, not recruiting
N/A
4000
US
Chiesi USA, Inc., Duke University
Myocardial Infarction
06/25
06/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
06/26
06/31
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
NCT05312164: Physio-Anatomy Clinical Data Collection Study

Recruiting
N/A
150
US
HF-OCT Imaging, FFR Pressure Wire, Angiography
Gentuity, LLC
Coronary Stenosis
12/25
12/25
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Rothman, Russell L
PRECIDENTD, NCT05390892: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Recruiting
4
6000
US
SGLT2 inhibitor, GLP-1 receptor agonist
Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute
Type2Diabetes, ASCVD
03/29
03/29
NCT04042467: Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention

Completed
N/A
900
US
Greenlight Plus, Greenlight
Vanderbilt University Medical Center, Patient-Centered Outcomes Research Institute, Duke University, University of North Carolina, Chapel Hill, Stanford University, NYU Langone Health, University of Miami, Johns Hopkins University
Behavior, Health, Child Obesity
01/24
01/24
Kitko, Carrie
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Antithymocyte globulin rabbit ATG, Grafalon, Imtix, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
12/25
01/27
NCT05090384: Pediatric GVHD Low Risk Steroid Taper Trial

Recruiting
2
50
Canada, US
Prednisone
John Levine
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
03/25
03/25
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Checkmark Pivotal data from ROCKstar trial in cGVHD
Jul 2021 - Jul 2021: Pivotal data from ROCKstar trial in cGVHD
Checkmark Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Jun 2021 - Jun 2021: Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Checkmark Follow-up data from ROCKstar trial for cGVHD at ASH
More
Terminated
2
159
US
Belumosudil (KD025), REZUROCK
Kadmon, a Sanofi Company
Chronic Graft-versus-host-disease
12/23
12/23
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
NCT03842696: Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
1/2
49
US
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
06/25
06/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT04372524: Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

Recruiting
N/A
350
Canada, US
University of British Columbia
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
01/24
01/25
NCT03718546: Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors

Completed
N/A
754
US
Center for International Blood and Marrow Transplant Research, University of Pittsburgh
Quality of Life
10/24
10/24
CATCH, NCT04188912: Close Assessment and Testing for Chronic Graft Versus Host Disease, Study

Active, not recruiting
N/A
267
US
Biospecimen Collection, Optical Coherence Tomography, OCT, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Quality of Life Assessment, Medical Chart Review, Chart Review
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm
10/25
10/25
Davis, Elizabeth
NCT06422806: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Recruiting
3
180
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475
National Cancer Institute (NCI)
Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Undifferentiated Pleomorphic Sarcoma
06/26
06/26
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

Recruiting
2
26
US
Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma
12/18
12/18
NCT02923778: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Active, not recruiting
2
40
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
12/25
12/25
NCT04595747: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting
2
48
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rogaratinib, BAY-1163877, BAY1163877
National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
07/26
07/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
NCT03212274: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
2
145
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
07/25
07/25
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
ZIABC011078, NCT03141684: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Hourglass Oct 2024 - Dec 2024 : Regulatory approval for alveolar soft part sarcoma
Checkmark Approved for adult and pediatric patients 2 years of age and older with alveolar soft part sarcoma based on ML39345 study
Dec 2022 - Dec 2022: Approved for adult and pediatric patients 2 years of age and older with alveolar soft part sarcoma based on ML39345 study
Active, not recruiting
2
63
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
10/25
10/25
NCT05836571: Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Recruiting
2
66
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute LAO
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
05/26
05/26
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting
1/2
333
US
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
02/26
05/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
EMPOWER, NCT04598698: The Study: Endometriosis Diagnosis Using MicroRNA

Active, not recruiting
N/A
750
NA
Dot Laboratories, Inc.
Endometriosis
05/23
12/24
NCT04925089: Localized Leiomyosarcoma Biomarker Protocol

Recruiting
N/A
40
US
Blood and Tissue collection
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Leiomyosarcoma
04/25
04/25
GPRPL, NCT05444283: Genomic Predictors of Recurrent Pregnancy Loss

Recruiting
N/A
1000
US
Yale University, Johns Hopkins University, University of Texas at Austin, Penn State University, Northwestern University, The University of Texas Health Science Center at San Antonio, Wayne State University, Columbia University, University of Colorado, Denver, University of Oklahoma, University of Chicago, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recurrent Pregnancy Loss
12/26
12/26
NCT05653388: Metastatic Leiomyosarcoma Biomarker Protocol

Recruiting
N/A
200
US, RoW
Plasma Collection
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Leiomyosarcoma
12/26
12/26
ACTRN12616000861459p: Quantity of IV insulin required to keep blood glucose levels within target range after a high protein/high fat meal.

Not yet recruiting
N/A
13
 
Princess Margaret Hospital, Juvenile Diabetes Research Fund
Type 1 Diabetes
 
 
ACTRN12620000947909: Using continuous glucose monitoring to detect early dysglycaemia in children participating in the Environmental Determinants of Islet Autoimmunity (ENDIA) study (Sub Protocol)

Recruiting
N/A
70
 
Telethon Kids Institute, Diabetes Research WA, Australasian Paediatric Endocrine Group, Women's and Children's Hospital Foundation, The Leona M. and Harry B. Helmsley Foundation, Juvenile Diabetes Research Foundation, Raine Medical Research Foundation
Type 1 Diabetes
 
 
ACTRN12621000366853: The mobile food record: A pilot study using images to assess dietary intake in children and adolescents with type 1 diabetes

Completed
N/A
50
 
Telethon Kids Institute, Telethon Kids Institute
Type 1 Diabetes
 
 
ACTRN12621000443897: Quality or Quantity: The Role of Carbohydrate in the Health of Children with Diabetes.

Completed
N/A
100
 
Telethon Kids Institute, Future Health Research Innovation Fund-WA Research fund
Type 1 Diabetes
 
 
Keedy, Vicki
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
NCT05580588: Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Terminated
2
14
US
SPH4336
Shanghai Pharma Biotherapeutics USA Inc.
Liposarcoma, Dedifferentiated
10/24
10/24
Mocco, J
SISTER, NCT05948566: Strategy for Improving Stroke Treatment Response

Recruiting
2
300
US
TS23
Translational Sciences, Inc., University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), Medical University of South Carolina, University of Arizona
Ischemic Stroke
07/27
12/27
PHIL dAVF, NCT03467542: PHIL in the Treatment of Intracranial dAVF.

Completed
N/A
64
US
PHIL® Liquid Embolic System
Microvention-Terumo, Inc.
Arteriovenous Dural Fistula
12/22
12/22
NCT02654015: INVEST Feasibility - Minimally Invasive Endoscopic Surgery With Apollo in Patients With Brain Hemorrhage

Completed
N/A
50
US
Apollo MIES, ICH - Apollo System, Medical Management, MM, ICH - Medical Management
J. Mocco, MOUNT SINAI HOSPITAL, University at Buffalo
Intracranial Hemorrhage
09/22
09/22
NCT02661672: INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage

Completed
N/A
38
US
Apollo Device, ICH - Apollo System, Artemis Device
J. Mocco, MOUNT SINAI HOSPITAL, University at Buffalo
Intracranial Hemorrhage
11/22
11/22
FEAT, NCT01655784: Framing Eighteen Coils in Cerebral Aneurysms Trial

Completed
N/A
651
US
Coil Embolization with larger Diameter Coils, Eighteen Coils, Cerebral Aneurysm Embolization, Aneurysm Coils, Coil Embolization with Standard Diameter Coils
Vanderbilt University Medical Center, Stryker Neurovascular
Cerebral Aneurysm
02/24
02/24
STEP, NCT06289985: StrokeNet Thrombectomy Endovascular Platform

Recruiting
N/A
2000
US
Endovascular thrombectomy with any FDA-approved category POL or NRY device, EVT, Endovascular Recanalization Therapy, Endovascular Therapy, Medical Management
Medical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, University of Virginia, Berry Consultants, University of California, Los Angeles, MOUNT SINAI HOSPITAL, The Cooper Health System, University of Pittsburgh Medical Center, Stony Brook University, University at Buffalo
Ischemic Stroke
01/29
01/30
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment

Recruiting
N/A
240
RoW
Minimally invasive hematoma evacuation
University of Melbourne
Intra Cerebral Hemorrhage, Stroke
12/25
12/26
TESTED, NCT05911568: Treatment With Endovascular Intervention for STroke Patients With Existing Disability

Recruiting
N/A
1060
US
Endovascular Stroke Treatment, Medical Management
University of Cincinnati, Patient-Centered Outcomes Research Institute, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai
Stroke, Stroke, Acute, Stroke, Ischemic
01/28
04/28
Massion, Pierre P
NCT00898313: Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Recruiting
N/A
4000
US
comparative genomic hybridization, gene expression microarray analysis, proteomic profiling analysis, biologic sample preservation procedure, nasal brushing, Blood draw, Urine collection, sputum sample, fluorescence bronchoscopy with airway biopsy, fine needle aspiration of the lung, thoracentesis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Lung Cancer
01/25
01/25
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
DECAMP-2, NCT02504697: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

Active, not recruiting
N/A
665
US
Biosamples from airway and blood
Boston University, American College of Radiology Imaging Network
Pulmonary Disease
12/27
12/27
Lindman, Brian R
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
06/26
06/31
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
MOBILE HEART, NCT06479876: Home-Based Cardiac Rehabilitation for Patients With Heart Failure

Recruiting
N/A
100
US
HBCR
Vanderbilt University Medical Center
Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases
07/25
10/25
ALERT, NCT06099665: Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

Recruiting
N/A
2626
US
Automated alert
Tempus AI, Medtronic
Aortic Valve Stenosis, Mitral Regurgitation
12/25
12/25
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
HOMERUNHITTER, NCT06077201: Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions

Recruiting
N/A
375
US
HBCR hands-off, HBCR interactive
Vanderbilt University Medical Center, Medical University of South Carolina, University of Pittsburgh, Duke Clinical Research Institute, National Institute on Aging (NIA), University of Michigan, The Cleveland Clinic, University of Colorado, Denver, Piedmont Healthcare, Inova Fairfax Hospital, Wake Forest University Health Sciences, Morristown Medical Center
Valvular Heart Disease
06/26
10/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Hamilton, Betty
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
NCT05544032: Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Available
N/A
NA
axatilimab, INCA34176
Incyte Corporation
Chronic Graft Vs. Host Disease
 
 
NCT06649201: Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

Recruiting
N/A
40
US
Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation
Case Comprehensive Cancer Center, Incyte Corporation
Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
02/26
02/27
CATCH, NCT04188912: Close Assessment and Testing for Chronic Graft Versus Host Disease, Study

Active, not recruiting
N/A
267
US
Biospecimen Collection, Optical Coherence Tomography, OCT, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Quality of Life Assessment, Medical Chart Review, Chart Review
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm
10/25
10/25
NCT04431479: Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Recruiting
N/A
200
Canada, US
Biospecimen Collection, Medical Chart Review, Chart Review, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
08/26
08/26
Goldfarb, Michael
MINT, NCT02981407: Myocardial Ischemia and Transfusion

Completed
3
3506
Europe, Canada, US, RoW
Red Blood Cell Transfusion
Rutgers, The State University of New Jersey, University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Infarction, Anemia
05/23
10/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
FAM-CICU, NCT05528185: Family Participation in CICU Rounds: RCT

Recruiting
N/A
220
Canada
Direct participation of the family member in the daily rounds
Lady Davis Institute
Family Members, Health Care Providers, Engagement, Patient
12/23
12/23
FAME, NCT05659485: Measuring Family Engagement in Care (The Study)

Recruiting
N/A
198
Canada
Lady Davis Institute, Jewish General Hospital, Canadian Institutes of Health Research (CIHR)
Family Engagement, Patient-centered Care, Critical Care
12/25
12/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stein, Charles
NCT03649178: Dietary Salt in Rheumatoid Arthritis

Completed
N/A
18
US
salt
Vanderbilt University Medical Center, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Rheumatoid Arthritis
09/24
12/24
Lee, Stephanie J
NCT04572815: Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant

Recruiting
2
116
US
Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Ustekinumab, CNTO 1275, CNTO1275, Immunoglobulin G1, Anti-(Human Interleukin-12 Subunit beta (IL-12B, CLMF p40, NKSF2)) (Human Monoclonal CNTO 1275 gamma1-chain), Disulfide with Human Monoclonal CNTO 1275 kappa-chain, Dimer, Stelara
Fred Hutchinson Cancer Center
Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid System Neoplasm
03/26
09/27
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
12/25
01/27
NCT05996627: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Recruiting
2
82
US
Belumosudil, KD 025, KD-025, KD025, Rho-associated Coiled-coil Kinase 2 Inhibitor KD025, ROCK-II Inhibitor KD025, ROCK2 Inhibitor KD025, SLx 2119, SLx-2119, SLx2119, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Electronic Health Record Review, Placebo Administration
Fred Hutchinson Cancer Center, Sanofi
Chronic Graft Versus Host Disease
05/27
12/27
NCT04111497: Glasdegib for Chronic Graft-Versus-Host Disease

Terminated
1/2
15
US
Glasdegib, 1095173-27-5, PF 04449913, PF-04449913, PF04449913
Fred Hutchinson Cancer Center, Pfizer
Chronic Graft Versus Host Disease, Fasciitis
08/23
08/23
NCT00637689: Improving Outcomes Assessment in Chronic GVHD

Active, not recruiting
N/A
601
US
Fred Hutchinson Cancer Center, University of Minnesota, Stanford University, Dana-Farber Cancer Institute, Vanderbilt University, Medical College of Wisconsin, Washington University School of Medicine, H. Lee Moffitt Cancer Center and Research Institute, Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
05/17
02/27
NCT01902576: Chronic GVHD Response Measures Validation

Active, not recruiting
N/A
383
US
Fred Hutchinson Cancer Center
Graft vs Host Disease
09/19
02/27
PROHIBIT-ICH, NCT03863665: Prevention of Hypertensive Injury to the Brain by Intensive Treatment of Blood Pressure After Intracerebral Haemorrhage

Terminated
N/A
86
Europe
A&D BP Digital Blood Pressure Monitor (UA-767PBT-Ci) CE Declaration UA-767PBT-Ci
University College, London, University of Oxford, The Stroke Association, United Kingdom
Intracerebral Hemorrhage
05/22
04/23
NCT06202677: Effectiveness of a Self-guided Mobile Application in Improving Obsessive Compulsive Disorder Symptoms

Active, not recruiting
N/A
225
RoW
Self-guided program on obsessive compulsive disorder, Self-guided program on cooperation
National University of Singapore, Intellect Pte. Ltd.
Obsessive-Compulsive Disorder
03/24
07/24
BMT CTN 1702, NCT03904134: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation

Active, not recruiting
N/A
1753
US
Donor Search Prognosis Score
Center for International Blood and Marrow Transplant Research, National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI), Blood and Marrow Transplant Clinical Trials Network, National Marrow Donor Program, Medical College of Wisconsin
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease
06/24
03/25
CATCH, NCT04188912: Close Assessment and Testing for Chronic Graft Versus Host Disease, Study

Active, not recruiting
N/A
267
US
Biospecimen Collection, Optical Coherence Tomography, OCT, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Quality of Life Assessment, Medical Chart Review, Chart Review
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm
10/25
10/25
NCT04431479: Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Recruiting
N/A
200
Canada, US
Biospecimen Collection, Medical Chart Review, Chart Review, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
08/26
08/26
Berlin, Jordan
NCT03641313: Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Active, not recruiting
2
14
US
Berzosertib, 2-Pyrazinamine, 3-(3-(4-((Methylamino)methyl)phenyl)-5-isoxazolyl)-5-(4-((1-methylethyl)sulfonyl)phenyl)-, M 6620, M6620, VX 970, VX-970, VX970, Computed Tomography Assisted Biopsy, Computed Tomography Biopsy, Computed Tomography-Guided Needle Biopsy, CT Assisted Biopsy, CT Guided Biopsy, Endoscopic Biopsy, Endoscopy and Biopsy, Irinotecan, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
07/24
12/25
SWOG S1609, NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Checkmark From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Yervoy for metaplastic breast cancer
Checkmark From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Jun 2020 - Jun 2020: From cohort 36 of DART trial in combination with Opdivo for metaplastic breast cancer
Checkmark In combination with yervoy in aggressive neuroendocrine tumors
More
Active, not recruiting
2
818
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute (NCI)
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma
05/26
05/26
NCT03263429: Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Completed
1/2
29
US
Glutaminase Inhibitor CB-839, Panitumumab, Irinotecan Hydrochloride (phase I only), Laboratory Biomarker Analysis, Pharmacological Study, Imaging with 11C-Glutamine PET/CT scans and 18F-FSPG PET/CT scans
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), Calithera Biosciences, Inc
Colorectal Cancer, Metastatic Colorectal Cancer, RAS Wild Type Colorectal Cancer, Refractory Colorectal Cancer
08/23
12/23
LIBRETTO-001, NCT03157128 / 2017-000800-59: A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Hourglass Jan 2022 - Dec 2022 : Submission for lung cancer
Hourglass Apr 2022 - Dec 2022 : Approval in China for RET+NSCLC, medullary thyroid cancer and thyroid cancer
Checkmark From LIBRETTO-001 trial in RET fusion-positive NSCLC
Aug 2020 - Aug 2020: From LIBRETTO-001 trial in RET fusion-positive NSCLC
Checkmark Granted for advanced RET fusion+ve 2L thyroid cancer [LIBRETTO-001]
More
Active, not recruiting
1/2
856
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Eli Lilly and Company, Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
02/25
02/26
DF1001-001, NCT04143711 / 2019-004706-10: Study of DF1001 in Patients with Advanced Solid Tumors

Recruiting
1/2
378
Europe, US, RoW
DF1001, Nivolumab, Nab paclitaxel, Sacituzumab Govitecan-hziy
Dragonfly Therapeutics, Dragonfly Therapeutics, Inc.
Solid Tumor, Adult
10/26
12/26
NCT05121948: A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)

Terminated
1
35
US
HC-7366
HiberCell, Inc., Covance
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer, Transitional Cell Carcinoma of the Bladder, Other Solid Tumors, Clear Cell Renal Cell Carcinoma
02/24
03/24
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Recruiting
1
64
US
RBS2418, Pembrolizumab
Riboscience, LLC., Oncobay Clinical, Inc
Advanced Cancer
09/25
10/25
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
NCT05753722: A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

Recruiting
1
270
US
PRTH-101, Pembrolizumab
Incendia Therapeutics
Advanced or Metastatic Solid Tumors
09/27
09/27
Barker, Colin
CAMEO, NCT04076813: Cangrelor in Acute Myocardial Infarction: Effectiveness and Outcomes Registry

Active, not recruiting
N/A
4000
US
Chiesi USA, Inc., Duke University
Myocardial Infarction
06/25
06/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
06/26
06/31
CorCinch-HF, NCT04331769: Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present with Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF): the CORCINCH-HF Study

Recruiting
N/A
400
Europe, US, RoW
AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
Ancora Heart, Inc.
Heart Failure with Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
12/26
12/30
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
NCT05312164: Physio-Anatomy Clinical Data Collection Study

Recruiting
N/A
150
US
HF-OCT Imaging, FFR Pressure Wire, Angiography
Gentuity, LLC
Coronary Stenosis
12/25
12/25
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
NCT04198870: MitraClip REPAIR MR Study

Recruiting
N/A
500
Europe, Canada, US
MitraClip™ device implantation, Mitral Valve Repair Surgery
Abbott Medical Devices
Mitral Valve Regurgitation
04/26
04/34
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Rothman, Russell L
PRECIDENTD, NCT05390892: PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Recruiting
4
6000
US
SGLT2 inhibitor, GLP-1 receptor agonist
Brigham and Women's Hospital, Patient-Centered Outcomes Research Institute
Type2Diabetes, ASCVD
03/29
03/29
NCT04042467: Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention

Completed
N/A
900
US
Greenlight Plus, Greenlight
Vanderbilt University Medical Center, Patient-Centered Outcomes Research Institute, Duke University, University of North Carolina, Chapel Hill, Stanford University, NYU Langone Health, University of Miami, Johns Hopkins University
Behavior, Health, Child Obesity
01/24
01/24
Kitko, Carrie
NCT05457556: Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome

Recruiting
3
435
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Busulfan, 1, 4-Bis[methanesulfonoxy]butane, BUS, Busilvex, Bussulfam, Busulfanum, Busulfex, Busulphan, CB 2041, CB-2041, Glyzophrol, GT 41, GT-41, Joacamine, Methanesulfonic Acid Tetramethylene Ester, Methanesulfonic acid, tetramethylene ester, Mielucin, Misulban, Misulfan, Mitosan, Myeleukon, Myeloleukon, Myelosan, Mylecytan, Myleran, Sulfabutin, Tetramethylene Bis(methanesulfonate), Tetramethylene bis[methanesulfonate], WR-19508, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Echocardiography, EC, Fludarabine, Fluradosa, Haploidentical Hematopoietic Cell Transplantation, Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Antithymocyte Globulin Rabbit, Antithymocyte globulin rabbit ATG, Grafalon, Imtix, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, Thymoglobulin, Lumbar Puncture, LP, Spinal Tap, Matched Unrelated Donor Hematopoietic Cell Transplantation, MUD-HCT, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalan for Injection-Hepatic Delivery System, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Mycophenolate Mofetil, CellCept, MMF, Myeloablative Conditioning, Myeloablation, Myeloablative, Myeloablative Cytoreduction, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, T-Cell Depletion Therapy, T-Cell Depletion, T-Lymphocyte Depletion Therapy, Tacrolimus, FK 506, FK-506, FK506, Fujimycin, Hecoria, Prograf, Protopic, Tacforius, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, SH 105, SH-105, SH105, STEPA, Tepadina, Tepylute, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Total-Body Irradiation, SCT_TBI, TBI, Total Body Irradiation, Whole Body, Whole Body Irradiation, Whole-Body Irradiation
Children's Oncology Group
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome
12/27
12/27
NCT04198922: Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease

Recruiting
2
50
US
Acalabrutinib, 1420477-60-6, ACP-196, Benzamide, Bruton Tyrosine Kinase Inhibitor ACP-196, Questionnaire Administration
Fred Hutchinson Cancer Center, AstraZeneca
Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm
12/25
01/27
NCT05090384: Pediatric GVHD Low Risk Steroid Taper Trial

Recruiting
2
50
Canada, US
Prednisone
John Levine
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
03/25
03/25
ROCKstar, NCT03640481: Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

Checkmark Pivotal data from ROCKstar trial in cGVHD
Jul 2021 - Jul 2021: Pivotal data from ROCKstar trial in cGVHD
Checkmark Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Jun 2021 - Jun 2021: Follow-up analysis data from ROCKstar trial for cGVHD at EHA 2021
Checkmark Follow-up data from ROCKstar trial for cGVHD at ASH
More
Terminated
2
159
US
Belumosudil (KD025), REZUROCK
Kadmon, a Sanofi Company
Chronic Graft-versus-host-disease
12/23
12/23
CASSIOPEIA, NCT03876769 / 2017-002116-14: Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

Calendar Jan 2025 - Dec 2025: Data from CASSIOPEIA trial for 1L acute ALL
Active, not recruiting
2
121
Europe, Canada, US
CTL019
Novartis Pharmaceuticals, Children's Oncology Group
B-Cell Acute Lymphoblastic Leukemia
10/27
10/27
NCT03842696: Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

Recruiting
1/2
49
US
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
06/25
06/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
NCT04372524: Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study

Recruiting
N/A
350
Canada, US
University of British Columbia
Chronic Graft-versus-Host-Disease, Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Blood Cancer, Non-Malignant Hematologic and Lymphocytic Disorder
01/24
01/25
NCT03718546: Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors

Completed
N/A
754
US
Center for International Blood and Marrow Transplant Research, University of Pittsburgh
Quality of Life
10/24
10/24
CATCH, NCT04188912: Close Assessment and Testing for Chronic Graft Versus Host Disease, Study

Active, not recruiting
N/A
267
US
Biospecimen Collection, Optical Coherence Tomography, OCT, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Quality of Life Assessment, Medical Chart Review, Chart Review
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm
10/25
10/25
Davis, Elizabeth
NCT06422806: Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Recruiting
3
180
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Diagnostic Imaging, Medical Imaging, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Pembrolizumab, BCD-201, GME 751, GME751, Keytruda, Lambrolizumab, MK 3475, MK-3475, MK3475, Pembrolizumab Biosimilar BCD-201, Pembrolizumab Biosimilar GME751, Pembrolizumab Biosimilar QL2107, Pembrolizumab Biosimilar RPH-075, QL2107, RPH 075, RPH-075, RPH075, SCH 900475, SCH-900475, SCH900475
National Cancer Institute (NCI)
Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Unresectable Undifferentiated Pleomorphic Sarcoma
06/26
06/26
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
NCT03233698: Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery

Recruiting
2
26
US
Atezolizumab, Laboratory Biomarker Analysis, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma
12/18
12/18
NCT02923778: Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

Active, not recruiting
2
40
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Talimogene Laherparepvec, ICP34.5-, ICP47-deleted Herpes Simplex Virus 1 (HSV-1) Incorporating the Human GM-CSF Gene, Imlygic, JS1 34.5-hGMCSF 47- pA-, T-VEC
National Cancer Institute (NCI)
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
12/25
12/25
NCT04595747: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting
2
48
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rogaratinib, BAY-1163877, BAY1163877
National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
07/26
07/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT05979415: Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes

Terminated
2
8
US
Apomorphine Cartridge, placebo
Alexza Pharmaceuticals, Inc., Peachtree BioResearch Solutions, DSG, ISS, Inc.
Parkinson Disease
02/24
02/24
NCT03212274: Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Active, not recruiting
2
145
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Glioblastoma, Recurrent Cholangiocarcinoma, Recurrent Glioma, Recurrent Malignant Solid Neoplasm, WHO Grade 2 Glioma, WHO Grade 3 Glioma
07/25
07/25
Actuate 1801, NCT03678883 / 2018-003739-32: 9-ING-41 in Patients with Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc., Actuate Therapeutics Inc
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
01/25
01/26
ZIABC011078, NCT03141684: Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma

Hourglass Oct 2024 - Dec 2024 : Regulatory approval for alveolar soft part sarcoma
Checkmark Approved for adult and pediatric patients 2 years of age and older with alveolar soft part sarcoma based on ML39345 study
Dec 2022 - Dec 2022: Approved for adult and pediatric patients 2 years of age and older with alveolar soft part sarcoma based on ML39345 study
Active, not recruiting
2
63
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
National Cancer Institute (NCI)
Metastatic Alveolar Soft Part Sarcoma, Unresectable Alveolar Soft Part Sarcoma
10/25
10/25
NCT05836571: Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Recruiting
2
66
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cabozantinib, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS 734016, BMS-734016, BMS734016, Ipilimumab Biosimilar CS1002, MDX 010, MDX-010, MDX-CTLA4, MDX010, Yervoy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo
National Cancer Institute LAO
Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
05/26
05/26
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
BA3011-001, NCT03425279: CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients with Sarcoma

Active, not recruiting
1/2
300
US, RoW
CAB-AXL-ADC, PD-1 inhibitor
BioAtla, Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
01/25
01/25
KEYNOTE A99, NCT04198766: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Recruiting
1/2
333
US
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, KEYTRUDA, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Alimta®, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Inhibrx Biosciences, Inc, Merck Sharp & Dohme LLC
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
02/26
05/26
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
EMPOWER, NCT04598698: The Study: Endometriosis Diagnosis Using MicroRNA

Active, not recruiting
N/A
750
NA
Dot Laboratories, Inc.
Endometriosis
05/23
12/24
NCT04925089: Localized Leiomyosarcoma Biomarker Protocol

Recruiting
N/A
40
US
Blood and Tissue collection
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Leiomyosarcoma
04/25
04/25
GPRPL, NCT05444283: Genomic Predictors of Recurrent Pregnancy Loss

Recruiting
N/A
1000
US
Yale University, Johns Hopkins University, University of Texas at Austin, Penn State University, Northwestern University, The University of Texas Health Science Center at San Antonio, Wayne State University, Columbia University, University of Colorado, Denver, University of Oklahoma, University of Chicago, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recurrent Pregnancy Loss
12/26
12/26
NCT05653388: Metastatic Leiomyosarcoma Biomarker Protocol

Recruiting
N/A
200
US, RoW
Plasma Collection
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Leiomyosarcoma
12/26
12/26
ACTRN12616000861459p: Quantity of IV insulin required to keep blood glucose levels within target range after a high protein/high fat meal.

Not yet recruiting
N/A
13
 
Princess Margaret Hospital, Juvenile Diabetes Research Fund
Type 1 Diabetes
 
 
ACTRN12620000947909: Using continuous glucose monitoring to detect early dysglycaemia in children participating in the Environmental Determinants of Islet Autoimmunity (ENDIA) study (Sub Protocol)

Recruiting
N/A
70
 
Telethon Kids Institute, Diabetes Research WA, Australasian Paediatric Endocrine Group, Women's and Children's Hospital Foundation, The Leona M. and Harry B. Helmsley Foundation, Juvenile Diabetes Research Foundation, Raine Medical Research Foundation
Type 1 Diabetes
 
 
ACTRN12621000366853: The mobile food record: A pilot study using images to assess dietary intake in children and adolescents with type 1 diabetes

Completed
N/A
50
 
Telethon Kids Institute, Telethon Kids Institute
Type 1 Diabetes
 
 
ACTRN12621000443897: Quality or Quantity: The Role of Carbohydrate in the Health of Children with Diabetes.

Completed
N/A
100
 
Telethon Kids Institute, Future Health Research Innovation Fund-WA Research fund
Type 1 Diabetes
 
 
Keedy, Vicki
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
NCT05580588: Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Terminated
2
14
US
SPH4336
Shanghai Pharma Biotherapeutics USA Inc.
Liposarcoma, Dedifferentiated
10/24
10/24
Mocco, J
SISTER, NCT05948566: Strategy for Improving Stroke Treatment Response

Recruiting
2
300
US
TS23
Translational Sciences, Inc., University of Cincinnati, National Institute of Neurological Disorders and Stroke (NINDS), Medical University of South Carolina, University of Arizona
Ischemic Stroke
07/27
12/27
PHIL dAVF, NCT03467542: PHIL in the Treatment of Intracranial dAVF.

Completed
N/A
64
US
PHIL® Liquid Embolic System
Microvention-Terumo, Inc.
Arteriovenous Dural Fistula
12/22
12/22
NCT02654015: INVEST Feasibility - Minimally Invasive Endoscopic Surgery With Apollo in Patients With Brain Hemorrhage

Completed
N/A
50
US
Apollo MIES, ICH - Apollo System, Medical Management, MM, ICH - Medical Management
J. Mocco, MOUNT SINAI HOSPITAL, University at Buffalo
Intracranial Hemorrhage
09/22
09/22
NCT02661672: INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage

Completed
N/A
38
US
Apollo Device, ICH - Apollo System, Artemis Device
J. Mocco, MOUNT SINAI HOSPITAL, University at Buffalo
Intracranial Hemorrhage
11/22
11/22
FEAT, NCT01655784: Framing Eighteen Coils in Cerebral Aneurysms Trial

Completed
N/A
651
US
Coil Embolization with larger Diameter Coils, Eighteen Coils, Cerebral Aneurysm Embolization, Aneurysm Coils, Coil Embolization with Standard Diameter Coils
Vanderbilt University Medical Center, Stryker Neurovascular
Cerebral Aneurysm
02/24
02/24
STEP, NCT06289985: StrokeNet Thrombectomy Endovascular Platform

Recruiting
N/A
2000
US
Endovascular thrombectomy with any FDA-approved category POL or NRY device, EVT, Endovascular Recanalization Therapy, Endovascular Therapy, Medical Management
Medical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, University of Virginia, Berry Consultants, University of California, Los Angeles, MOUNT SINAI HOSPITAL, The Cooper Health System, University of Pittsburgh Medical Center, Stony Brook University, University at Buffalo
Ischemic Stroke
01/29
01/30
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment

Recruiting
N/A
240
RoW
Minimally invasive hematoma evacuation
University of Melbourne
Intra Cerebral Hemorrhage, Stroke
12/25
12/26
TESTED, NCT05911568: Treatment With Endovascular Intervention for STroke Patients With Existing Disability

Recruiting
N/A
1060
US
Endovascular Stroke Treatment, Medical Management
University of Cincinnati, Patient-Centered Outcomes Research Institute, University of California, Los Angeles, Icahn School of Medicine at Mount Sinai
Stroke, Stroke, Acute, Stroke, Ischemic
01/28
04/28
Massion, Pierre P
NCT00898313: Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Recruiting
N/A
4000
US
comparative genomic hybridization, gene expression microarray analysis, proteomic profiling analysis, biologic sample preservation procedure, nasal brushing, Blood draw, Urine collection, sputum sample, fluorescence bronchoscopy with airway biopsy, fine needle aspiration of the lung, thoracentesis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Lung Cancer
01/25
01/25
NCT04165564: DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers

Active, not recruiting
N/A
85
US
Institutional standard of care, Biosamples of airway and blood
Boston University, Johnson & Johnson, American College of Radiology Imaging Network
Pulmonary Disease
12/26
12/26
DECAMP-2, NCT02504697: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

Active, not recruiting
N/A
665
US
Biosamples from airway and blood
Boston University, American College of Radiology Imaging Network
Pulmonary Disease
12/27
12/27
Lindman, Brian R
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)

Active, not recruiting
N/A
178
Europe, Canada, US
SAPIEN 3 THV, Optimal Heart Failure Therapy
Cardiovascular Research Foundation, New York, Cardialysis BV, Avania
Aortic Valve Stenosis
02/23
02/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
06/26
06/31
NCT04482062: TRISCEND II Pivotal Trial

Active, not recruiting
N/A
1070
Europe, US
Edwards EVOQUE System, Transcatheter tricuspid valve replacement, Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Valve Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease, Heart Valve Diseases, Cardiovascular Diseases, Heart Failure
06/24
12/29
MOBILE HEART, NCT06479876: Home-Based Cardiac Rehabilitation for Patients With Heart Failure

Recruiting
N/A
100
US
HBCR
Vanderbilt University Medical Center
Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases
07/25
10/25
ALERT, NCT06099665: Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

Recruiting
N/A
2626
US
Automated alert
Tempus AI, Medtronic
Aortic Valve Stenosis, Mitral Regurgitation
12/25
12/25
CLASP II TR, NCT04097145: Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

Recruiting
N/A
870
Canada, US
Edwards PASCAL System, Transcatheter tricuspid valve repair (TTVr), Optimal Medical Therapy
Edwards Lifesciences
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
12/27
12/31
HOMERUNHITTER, NCT06077201: Home-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions

Recruiting
N/A
375
US
HBCR hands-off, HBCR interactive
Vanderbilt University Medical Center, Medical University of South Carolina, University of Pittsburgh, Duke Clinical Research Institute, National Institute on Aging (NIA), University of Michigan, The Cleveland Clinic, University of Colorado, Denver, Piedmont Healthcare, Inova Fairfax Hospital, Wake Forest University Health Sciences, Morristown Medical Center
Valvular Heart Disease
06/26
10/26
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Hamilton, Betty
Precision-T (PhIII component), NCT05316701: Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
3
174
US
Orca-T, Standard-of-Care, SOC
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Mixed Phenotype Acute Leukemia, Undifferentiated Leukemia, Myelodysplastic Syndrome, Acute Leukemia, Therapy-Related Myelodysplastic Syndrome
04/25
04/27
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
Precision-T, NCT04013685: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Active, not recruiting
1
255
US
Orca-T
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia
07/24
07/26
NKX101-101, NCT04623944: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Active, not recruiting
1
61
US
NKX101 - CAR NK cell therapy, Cyclophosphamide, Fludarabine, Cytarabine (ara-C), Decitabine
Nkarta, Inc.
Relapsed/Refractory AML, AML, Adult, MDS, Refractory Myelodysplastic Syndromes
10/24
07/39
NCT05544032: Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Available
N/A
NA
axatilimab, INCA34176
Incyte Corporation
Chronic Graft Vs. Host Disease
 
 
NCT06649201: Vulvovaginal Graft-versus-Host Disease: Diagnosis and Microbiome Evaluation

Recruiting
N/A
40
US
Vulvovaginal Symptom Questionnaire, Vaginal Microbiome Evaluation
Case Comprehensive Cancer Center, Incyte Corporation
Graft Vs Host Disease, Vulvovaginal Signs and Symptoms
02/26
02/27
CATCH, NCT04188912: Close Assessment and Testing for Chronic Graft Versus Host Disease, Study

Active, not recruiting
N/A
267
US
Biospecimen Collection, Optical Coherence Tomography, OCT, Spirometry, Survey Administration, Digital Photography, Quality-of-Life Assessment, Quality of Life Assessment, Medical Chart Review, Chart Review
Fred Hutchinson Cancer Center, National Cancer Institute (NCI), National Institutes of Health (NIH)
Hematopoietic and Lymphoid Cell Neoplasm
10/25
10/25
NCT04431479: Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study

Recruiting
N/A
200
Canada, US
Biospecimen Collection, Medical Chart Review, Chart Review, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Chronic Graft Versus Host Disease
08/26
08/26
Goldfarb, Michael
MINT, NCT02981407: Myocardial Ischemia and Transfusion

Completed
3
3506
Europe, Canada, US, RoW
Red Blood Cell Transfusion
Rutgers, The State University of New Jersey, University of Pittsburgh, National Heart, Lung, and Blood Institute (NHLBI)
Myocardial Infarction, Anemia
05/23
10/23
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

Active, not recruiting
3
1108
Europe, Canada, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
12/24
11/25
FAM-CICU, NCT05528185: Family Participation in CICU Rounds: RCT

Recruiting
N/A
220
Canada
Direct participation of the family member in the daily rounds
Lady Davis Institute
Family Members, Health Care Providers, Engagement, Patient
12/23
12/23
FAME, NCT05659485: Measuring Family Engagement in Care (The Study)

Recruiting
N/A
198
Canada
Lady Davis Institute, Jewish General Hospital, Canadian Institutes of Health Research (CIHR)
Family Engagement, Patient-centered Care, Critical Care
12/25
12/25
 

Download Options